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Summary
Background Few studies have been done of patterns of treatment during mass drug administration (MDA) to control 
neglected tropical diseases. We used routinely collected individual-level treatment records that had been collated for 
the Tuangamize Minyoo Kenya Imarisha Afya (Swahili for Eradicate Worms in Kenya for Better Health [TUMIKIA]) 
trial, done in coastal Kenya from 2015 to 2017. In this analysis we estimate the extent of and factors associated with 
the same individuals not being treated over multiple rounds of MDA, which we term systematic non-treatment.
Methods We linked the baseline population of the TUMIKIA trial randomly assigned to receive biannual community-
wide MDA for soil-transmitted helminthiasis to longitudinal records on receipt of treatment in any of the four 
treatment rounds of the study. We fitted logistic regression models to estimate the association of non-treatment in a 
given round with non-treatment in the previous round, controlling for identified predictors of non-treatment. We also 
used multinomial logistic regression to identify factors associated with part or no treatment versus complete treatment.
Findings 36 327 participants were included in our analysis: 16 236 children aged 2–14 years and 20 091 adults aged 15 years 
or older. The odds of having no treatment recorded was higher if a participant was not treated during the previous round 
of MDA (adjusted odds ratio [OR] 3·60, 95% CI 3·08–4·20 for children and 5·58, 5·01–6·21 for adults). For children, 
school attendance and rural residence reduced the odds of receiving part or no treatment, whereas odds were increased 
by least poor socioeconomic status and living in an urban or periurban household. Women had higher odds than men of 
receiving part or no treatment. However, when those with pregnancy or childbirth in the previous 2 weeks were excluded, 
women became more likely to receive complete treatment. Adults aged 20–25 years were the age group with the highest 
odds of receiving part (OR 1·41, 95% CI 1·22–1·63) or no treatment (OR 1·81, 95% CI 1·53–2·14).
Interpretation Non-treatment was associated with specific sociodemographic groups and characteristics and did not 
occcur at random. This finding has important implications for MDA programme effectiveness, the relevance of which 
will intensify as disease prevalence decreases and infections become increasingly clustered.
Funding Bill & Melinda Gates Foundation, Joint Global Health Trials Scheme of the Medical Research Council, 
UK Department for International Development, Wellcome Trust, Children’s Investment Fund Foundation, and 
London Centre for Neglected Tropical Diseases.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Control of the five neglected tropical diseases with the 
highest burden—schistosomiasis, lymphatic filariasis, 
onchocerciasis, trachoma, and infection with soil-trans-
mitted helminths—involves mass drug administration 
(MDA), in which an entire eligible population or the 
most vulnerable subgroups receive treatment without 
diagnosis.1 The success of MDA depends on the 
percentage of the target population who take treatment.2 
Mathematical modelling has highlighted the potential 
for systematic non-treatment, where the same individuals 
are not treated over multiple rounds of MDA, to drive 
persistence of infection reservoirs in the target popula-
tion.3–5 Studies have investigated determinants of reach 
and uptake within preventive MDA programmes, but 
few have quantified receipt of treatment over time in 
individuals to measure the extent of systematic non-
treatment.6–9 As with other neglected tropical diseases for 
which preventive chemotherapy is appropriate, guidance 
on optimising treatment for soil-transmitted helminths 
will need to be based on understanding of patterns and 
factors associated with non-treatment during MDA.10,11
The Tuangamize Minyoo Kenya Imarisha Afya 
(Swahili for Eradicate Worms in Kenya for Better Health 
[TUMIKIA]) trial was a 2-year community-based, cluster-
randomised controlled trial done between 2015 and 2017 
in Kwale county, Kenya, to evaluate the effectiveness and 
cost-effectiveness of school-based versus community-wide 
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deworming on transmission of soil-transmitted hel-
minths.12 Located on the south coast, Kwale is pre-
dominantly rural, is among the poorest counties, and has 
poor access to water and sanitation.12 Annual school-based 
deworming has been implemented in Kwale as part of the 
national programme since 2012, and community-based 
MDA for lymphatic filariasis has been implemented 
by the Kwale county Ministry of Health intermittently 
since 2003.13 The trial demonstrated that community-
wide deworming achieved high coverage across all key 
demographic groups and was more effec tive than annual 
school-based deworming at reducing prevalence and 
intensity of hookworm infection.14 In this analysis, we use 
routinely collected data on treatment across the four 
treatment rounds in the TUMIKIA trial to assess patterns 
of non-treatment and identify subgroups of the population 
at risk of systematic non-treatment.
Methods
Study design and participants
The TUMIKIA trial design, baseline findings, and effects 
have been described previously.12–14 Briefly, 120 community 
units (clusters) of approximately 1000 households were 
randomly assigned to receive albendazole through annual 
school-based treatment targeting children aged 2–14 years 
or through annual or biannual community-wide treat-
ment targeting all ages. The primary outcome was 
community hookworm prevalence, which was assessed at 
baseline and at 12 and 24 months through cross-sectional 
surveys. The trial protocol was approved by the Kenya 
Medical Research Institute and National Ethics Review 
Committee (SSC number 2826) and the London School 
of Hygiene & Tropical Medicine Ethics Committee, 
London, UK (7177). Written informed consent was sought 
from the household head or adult answering household-
level questionnaires.
In the present study, participants in the baseline survey 
who were randomly assigned to receive biannual treat-
ment were linked to their treatment records from the four 
rounds of MDA during the trial. We included individuals 
recorded to be aged 2 years or older at baseline and not 
recorded as deceased or migrated in any round.
Procedures
Households were enumerated at the start of the trial 
from listings provided by community health services 
and village leaders or from other community-based 
programmes. For each survey, 225 households per cluster 
were randomly selected from the enumeration listing. In 
consenting households, members were counted and their 
sociodemographic information and school attendance (for 
children) were recorded. Information was also collected 
on household assets, sanitation, hygiene, and water 
conditions. All data and GPS coordinates were collected 
on smartphones running the Android operating system 
and using SurveyCTO software (Dobility, Cambridge, MA, 
USA). Household locations were classified as urban, 
periurban, or rural, based on the 2015 World-Pop estimates 
of population density. Household remoteness was 
calculated as the Euclidean distance from a major road, 
using Open Street Map data. Location classification, 
remoteness calculation, and point-based extraction were 
Research in context
Evidence before this study
Control efforts for many neglected tropical diseases, including 
soil-transmitted helminths, schistosomiasis, lymphatic filariasis, 
onchocerciasis, and trachoma, focus on mass drug distribution 
(MDA), which is treatment of an entire eligible population or 
most vulnerable subgroups without diagnosis. The effectiveness 
of this approach for controlling morbidity or reducing 
transmission depends upon the percentage of the population 
treated in each round. Mathematical modelling has highlighted 
that persistent non-treatment of individuals across multiple 
MDA rounds could negatively affect interruption of transmission 
of soil-transmitted helminths. An earlier systematic review, 
on which we have based this study, also highlighted that few 
studies have quantified receipt of treatment over time. Improved 
understanding of patterns and factors associated with 
non-treatment across MDA rounds will benefit efforts to 
strengthen delivery and optimise treatment for soil-transmitted 
helminths and other neglected tropical diseases. 
Added value of this study
This analysis was done after linking the baseline population of 
the biannual MDA group in the TUMIKIA trial in Kwale County, 
Kenya, to longitudinal records of receipt of treatment in the 
four treatment rounds of the study. Among children (age 
2–14 years) and adults (age ≥15 years) we found that the same 
individuals repeatedly missed treatment. Although the 
proportion of participants who received no treatment in all 
four rounds was low, more than half of individuals received 
fewer than four treatments. For children, school attendance 
and rural residence were protective against receiving part or no 
treatment. Among adults, those aged 20–25 years were most 
likely to receive part or no treatment, and women were less 
likely than men to receive all four treatments. 
Implications of all the available evidence
Very few studies have quantitatively examined patterns of 
treatment across multiple rounds of MDA for control of 
neglected tropical diseases. Our results indicate distinct 
demographic subgroups that did not complete treatment. 
Further research is needed to examine how the extent of 
non-treatment might jeopardise MDA outcomes and how to 
strengthen MDA implementation approaches to increase 
coverage.
For World-Pop estimates of 
population density see 
http://www.worldpop.org.uk
For Open Street Map data see 
https://www.openstreetmap.org
Articles
www.thelancet.com/lancetgh   Vol 8   November 2020 e1420
done in ArcGIS version 10.3.13 House holds without GPS 
coordinates were given the village mode or mean value for 
categorical and continuous measures, respectively.
Four rounds of treatment were provided to the biannual 
group over 2 years. Before each round of treatment, 
community mobilisation activities took place that included 
forums with chiefs, ward administrators, and community 
health assistants, and meetings held by and door-to-door 
visits made by village elders.15 Participants received directly 
observed treatment with 400 mg albendazole provided 
through the WHO donation programme to the Govern-
ment of Kenya by GlaxoSmithKline (London, UK). 
Rounds one and three were provided in Jul 20–30, 2015, 
and May 26–June 3, 2016, respectively. Children aged 
2–14 years at school received treatment as part of the 
National School-Based Deworming Programme (round 1, 
June 4, 2015; round 2, May 26, 2016), and all other eligible 
recipients were treated by community health volunteers in 
community-wide house-to-house visits organised by the 
Kwale county Ministry of Health. Rounds two and four 
were provided in Nov 23−30, 2015, and Oct 28−Nov 4, 2016, 
and all people were treated during house-to-house visits. 
In these rounds, individuals also received 6 mg/kg 
diethylcarbamazine citrate as part of the restarted national 
lymphatic filariasis elimination programme.16 Community 
health volunteers received 1 day of training on the delivery 
of treatment, and each was responsible for treating 
approximately 120 households over 8 days per round. Trial 
staff provided training and technical support but were 
not involved in the delivery of treatment to household 
members.
Community health volunteers were provided with 
household enumeration listings for their area, which 
included the name of the head of each household and the 
TUMIKIA trial house identification number. On paper 
registers for each household, community health volunteers 
recorded the name, cluster, TUMIKIA trial house 
identification number, date of first visit, and number of 
revisits. They also listed the names, sexes, ages, and school 
enrolment status of all people who had been living in the 
house in the previous 3 months. Next to each individual 
listing, community health volunteers recorded whether 
albendazole was swallowed at the first visit or a revisit, 
along with the date of treatment and any side-effects 
experienced. If albendazole was not swallowed, this was 
classified as non-treatment and the reason was recorded 
from the following list: temporarily absent; pregnant; 
having given birth within 2 weeks; refused; younger than 
2 years; spat drug out; sick; migrated; died; or other. 
Participants recorded as recently dewormed (within the 
previous 8 weeks) in a school programme or at a health 
facility were recorded as having received treatment.
The paper treatment registers were collected and 
digitised with SurveyCTO following each community-wide 
treatment round. In rounds one, two, and three, only age 
and sex were digitised to estimate coverage by population 
group, but individuals’ names were not digitised. Names 
were included in the round-three digitised registers. This 
dataset was used to prepopulate an electronic data entry 
form for the digitisation and linkage of paper treatment 
registers from round four. Information from earlier 
rounds were retrospectively added. Data officers confirmed 
that the households in the paper and digitised records 
matched based on the names of household members. 
They then matched each individual’s name, age, and sex in 
in the paper register and digitised dataset. Following 
linkage of data for all four treatment rounds, another 
electronic data entry form was used to link households and 
individuals enumerated in the baseline cross-sectional 
household and parasitology survey to their treatment data.
Outcomes
An individual was classified as being treated if they were 
recorded as having been directly observed to swallow 
albendazole at home or reported to have received it in a 
school or health facility within the previous 8 weeks. 
Among those without recorded treatment, reasons for 
non-treatment were reported in the registers for only 
approximately 10% of children and 20% of adults. To 
address these missing data, within rounds we combined 
people with recorded reasons for non-treatment and those 
who had no record available for that round, and used the 
indicator non-treatment. Frequencies of recorded reasons 
for non-treatment and absence of records are provided in 
the appendix (p 2). An individual’s treatment status was 
summarised as complete if treatment was recorded in all 
four rounds, part if treatment was recorded in fewer than 
four rounds, and none if no treatment was recorded in 
any round.
Statistical analysis
Separate analyses were done for children aged 2–14 years, 
and adults (age ≥15 years) of associations between non-
treatment in round one and other factors; between non-
treatment in a given round and non-treatment in the 
previous round; and between factors and part or no 
treatment. In the TUMIKIA trial, 40 clusters were 
randomised to each treatment group, and 225 households 
per cluster were assessed in each prevalence survey, 
which was estimated would provide 80% power to detect 
8% difference in prevalence between groups with a 2⋅5% 
significance level.12 The sample size for this study was 
determined by the number of households in the baseline 
survey that were randomly assigned to the biannual 
treatment group.
We examined frequencies of non-treatment within and 
across rounds using histograms generated with the 
UpSetR package in R version 3.5.0.17 We estimated asso-
ciations between non-treatment in the first round and the 
following candidate predictor variables at baseline: age 
group; sex; school attendance by children; household 
socioeconomic status (least poor, poor, or poorest) derived 
from a factor analysis of assets; large household size 
(more than six members); remote house hold (>4 km from 
See Online for appendix
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Figure: Frequency of 
non-treatment within MDA 
rounds and patterns across 
the four MDA rounds
(A) Counts of non-treatment 
in 16 236 children aged 
2–14 years. (B) Counts of 
non-treatment in 
20 091 individuals aged 
15 years and older. 
No treatment during any 
round is shown on the right, 
each combination of part 
treatment in one, two, or three 
rounds, and complete 
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major road); and household location (urban and periurban 
vs rural). An additional predictor for children was based 
on whether the head of household was not treated in a 
given round.18
We fitted multivariable logistic regression models with 
robust SEs to account for clustering by household. We 
used a best-subset selection approach, modelling all 
possible combinations of candidate predictor variables 
hypothesised to influence an individual’s treatment status 
in round one. The final models consisted of the variables 
with the lowest Bayesian Information Criterion (appendix 
p 8).19 To estimate the association between non-treatment 
in round two, three, or four and non-treatment in the 
previous round, we fitted logistic regression models with 
robust SEs to account for clustering by household and 
applied random intercepts for individual. We controlled 
for the predictors of non-treatment identified for round 
one as potential confounders. Additionally, we investigated 
whether a round including school-based deworming or 
distri bution of diethylcarbamazine citrate affected the 
outcomes for children and adults, respectively.
Multivariable multinomial logistic regression models 
fitted with robust SEs were also used to account for 
clustering by household to identify factors associated with 
part or no treatment versus complete treatment, again 
assessing all possible subsets of the candidate predictors. 
For this model, we explored whether excluding rounds in 
which women of childbearing age (15–49 years) were not 
treated and were recorded as being pregnant, or having 
given birth in the previous 2 weeks changed the estimates 
for all adults. For all models, we examined the effects of 
different assumptions about individual censoring. For 
the main analysis we excluded individuals recorded as 
deceased or migrated, with additional sensitivity analyses 
to assess various assumptions based on the availability of 









2 to <5 3804 (23·4%) 37·5% ··
5 to <10 6756 (41·6%) 31·6% ··
10 to <15 5676 (35·0%) 30·8% ··
Sex
Male 8283 (51·0%) 32·9% ··
Female 7953 (49·0%) 32·5% ··
Attends school
No 4189 (25·8%) 38·0% 1 (ref)
Yes 12 047 (74·2%) 30·8% 0·66 (0·61–0·72)
Household
Head not treated
No 10 817 (66·6%) 22·0% 1 (ref)
Yes 5419 (33·4%) 54·0% 4·21 (3·77–4·71)
Socioeconomic status
Poorest 4813 (29·6%) 31·2% 1 (ref)
Poor 8463 (52·1%) 32·2% 1·07 (0·94–1·20)
Least poor 2960 (18·2%) 36·4% 1·32 (1·13–1·55)
Large size
No 7820 (48·2%) 32·2% ··
Yes 8416 (51·8%) 33·2% ··
Remote 
No 13 095 (80·6%) 33·6% 1 (ref)
Yes 3141 (19·3%) 28·9% 0·85 (0·73–0·98)
Urban or periurban location
No 12 079 (74·4%) 31·9% 1 (ref)
Yes 4157 (25·6%) 35·0% 1·17 (1·04–1·33)
*Multivariable logistic regression with robust SEs was done to account for 
household clustering. Odds ratios and 95% CIs are provided for the variables with 
the lowest Bayesian Information Criterion when all possible subsets of candidate 
predictors were modelled. 
Table 1: Frequency of non-treatment by individual and household 
characteristics and association with selected predictors in round one of 
mass drug administration among children









15 to <20 3889 (19·4%) 44·8% 1 (ref)
20 to <25 2612 (13·0%) 53·0% 1·39 (1·26–1·54)
25 to <30 2509 (12·5%) 47·4% 1·12 (1·01–1·25)
30 to <35 2243 (11·2%) 41·2% 0·87 (0·78–0·97)
35 to <45 3398 (16·9%) 33·9% 0·64 (0·58–0·70)
45 to <55 2329 (11·6%) 33·2% 0·63 (0·56–0·70)
55 to <65 1682 (8·4%) 32·9% 0·62 (0·55–0·71)
≥65 1429 (7·1%) 37·7% 0·77 (0·68–0·88)
Sex
Male 9364 (46·6%) 39·0% 1 (ref)
Female 10 727 (53·4%) 42·9% 1·14 (1·08–1·20)
Household
Socioeconomic status
Poorest 5226 (26·0%) 40·7% ··
Poor 10 451 (52·0%) 41·1% ··
Least poor 4414 (22·0%) 41·5% ··
Large size
No 12 080 (60·1%) 39·6% 1 (ref)
Yes 8011 (39·9%) 43·3% 1·13 (1·05–1·22)
Remote 
No 16 580 (82·5%) 41·1% ··
Yes 3511 (17·5%) 41·0% ··
Urban or periurban location 
No 14 174 (70·5%) 40·9% ··
Yes 5917 (29·5%) 41·5% ··
*Multivariable logistic regression with robust SEs was done to account for 
household clustering. Odds ratios and 95% CIs are provided for the variables with 
the lowest Bayesian Information Criterion when all possible subsets of candidate 
predictors were modelled.
Table 2: Frequency of non-treatment by individual and household 
characteristics and association with selected predictors in round one of 
mass drug administration among adults
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recorded treatment information (appendix p 3). All 
dataset assembly and analyses were done in Stata 
version 15.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
40 662 individuals in 7834 households surveyed at 
baseline in the TUMIKIA trial and randomly assigned to 
receive biannual treatment were considered for inclu-
sion in this analysis. Due to unavailability of treatment 
information from round two, data from one cluster 
(310 households and 1748 individuals) were excluded. 
25 households were linked to the same household 
treatment record as another baseline household and were 
excluded. 89 duplicated individual records were also 
excluded. Of the remaining 37 458 individuals enumerated 
in 7499 households and aged 2 years or older at the time 
of the TUMIKIA trial baseline survey, 1131 (3·0%) were 
recorded as being deceased or having moved away and, 
therefore, the final analysis included 36 327 (97·0%) 
individuals (appendix p 1).
Counts of non-treatment within MDA rounds and 
overall patterns of non-treatment across the four MDA 
rounds are shown in the figure. No treatment was 
recorded for 5310 (32·7%) of 16 236 children and 
8260 (41·1%) of 20 091 adults in round one. In children 
and adults, the occurrence of non-treatment was lowest 
in round one and increased over time.
Children reported to attend school had lower odds of 
non-treatment in round one than children reported not to 
attend school (table 1). The odds of non-treatment were 
raised substantially by the household head not having 
been treated, by least poor socioeconomic status, living in a 
less-remote household, and living in an urban or peri-
urban location. Among adults, age (particularly in the age 
group 20 to <25 years), sex, and large household size were 
associated with non-treatment in round one (table 2). 
Women were less likely than men to have treatment 
recorded when controlling for age and household size.
Among children, non-treatment in a previous round 
was associated with increased odds of non-treatment in 
the subsequent round (OR 3·60, 95% CI 3·08–4·20) 
when controlling for school attendance, non-treatment 
of the household head, household socioeconomic 
status, household remoteness, and urban or periurban 
household location. Controlling for whether school-
based deworming was implemented during a given 
round did not change the association (OR 3·59, 95% CI 
3·07–4·19). After censoring for lack of treatment 
register records, household socioeconomic status and 
remoteness were not selected as predictors of non-
treatment, and the association between non-treat ment 
in previous and the subsequent round was attenuated 
down towards null (appendix p 4).
Adults with no treatment recorded in a given round had 
substantially increased odds of not having treatment 
reported in the subsequent round (OR 5·58, 95% CI 
5·01–6·21) when controlling for age, sex, and household 
size. Concurrent distribution of diethylcarbamazine citrate 
did not meaningfully change the association (OR 5·58, 
95% CI 5·02–6·21). When censoring was considered, 
household size was no longer selected as a predictor of 
non-treatment and the estimated association between non-
treatment in previous and subsequent rounds was 
attenuated down towards null (appendix p 4).
Across the four rounds of MDA, no treatment was 
the least likely outcome among children (2170 [13·4%] 
of 16 236; table 3). Over half received part treatment 
(8670 [53·4%]), and around a third received complete 
treatment (5396 [33·2%]). Children who attended school 




Part treatment (n=8670) No treatment (n=2170)
Number (%) Odds ratio 
(95% CI)*
Number (%) Odds ratio 
(95% CI)*
Age group (years)
2 to <5 1214 (31·9%) 1982 (52·1%) ·· 608 (16·0%) ··
5 to <10 2327 (34·4%) 3559 (52·7%) ·· 870 (12·9%) ··
10 to <15 1855 (32·7%) 3129 (55·1%) ·· 692 (12·2%) ··
Sex
Male 2760 (33·3%) 4415 (53·3%) ·· 1108 (13·4%) ··
Female 2636 (33·1%) 4255 (53·5%) ·· 1062 (13·3%) ··
Attends school
No 1264 (30·2%) 2239 (53·4%) 1 (ref) 686 (16·4%) 1 (ref)
Yes 4132 (34·3%) 6431 (53·4%) 0·86 (0·79–0·93) 1484 (12·3%) 0·63 (0·55–0·71)
Household
Socioeconomic status
Poorest 1631 (33·9%) 2619 (54·4%) 1 (ref) 563 (11·7%) 1 (ref)
Poor 2878 (34·0%) 4453 (52·6%) 0·96 (0·85–1·09) 1132 (13·4%) 1·17 (0·99–1·39)
Least poor 887 (30·0%) 1598 (54·0%) 1·15 (0·98–1·34) 475 (16·0%) 1·67 (1·33–2·08)
Large size
No 2552 (32·6%) 4235 (54·2%) ·· 1033 (13·2%) ··
Yes 2844 (33·8%) 4435 (52·7%) ·· 1137 (13·5%) ··
Remote 
No 4302 (32·8%) 6981 (53·3%) ·· 1812 (13·8%) ··
Yes 1094 (34·8%) 1689 (53·8%) ·· 358 (11·4%) ··
Urban or periurban location
No 4156 (34·4%) 6317 (52·3%) 1 (ref) 1606 (13·3%) 1 (ref)
Yes 1240 (29·8%) 2353 (56·6%) 1·27 (1·12–1·44) 564 (13·6%) 1·22 (1·03–1·45)
*Multivariable logistic regression with robust SEs was done to account for household clustering. Odds ratios and 
95% CIs are provided for the variables with the lowest Bayesian Information Criterion when all possible subsets of 
candidate predictors were modelled. 
Table 3: Association between baseline individual and household characteristics and part or no treatment 
in children
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did not attend school. Higher socioeconomic status and 
living in an urban or periurban location notably increased 
the odds of recei ving part or no treatment. After data 
censoring, household socioeconomic status was no 
longer selected as a predictor, but interpretation of the 
models and other selected predictors did not change 
meaningfully (appendix p 5).
More than half of adults received part treatment 
(11 170 [55·6%] of 20 091), no treatment was received by 
3826 (19·0%), and a quarter received complete treat-
ment (5095 [25·4%]; table 4). The age group from 20 to 
younger than 25 years had the highest odds of receiving 
part or no treatment when controlling for sex and 
household size, whereas odds were reduced in those 
aged 30 years and older. Women had higher odds of 
receiving part or no treatment than men when con-
trolling for age and household size. With censoring, 
only age and sex were selected as predictors of non-
treatment (appendix p 6). In these alternate models, 
women had higher odds of receiving part treatment but 
lower odds of no treatment than men, and adults aged 
20–35 years had the highest odds of receiving part or no 
treatment.
Among 20 091 adults, 8694 women (43·3%) were of 
childbearing age and 1421 (16·3%) of these had pregnancy 
or birth within the previous 2 weeks recorded as the 
reason for non-treatment during at least one of the MDA 
rounds. 274 (19·3%) of these 1421 women did not receive 
treatment in two or more rounds. After excluding the 
rounds for women who were ineligible because of 
pregnancy or a recent birth, selected predictors were 
sex, age, large household size, and urban or periurban 
location, and women had lower odds than men of 
receiving part or no treatment (appendix p 7).
Discussion
Despite recognition of the potential threat of systematic 
non-treatment on the effectiveness of repeated MDA,9,11,20 
few longitudinal studies have assessed treatment at 
the individual level in large-scale MDA programmes. 
By combining household surveys and longitudinal 
treatment data, we were able to assess the number of 
Complete treatment 
(n=5095)
Part treatment (n=11 170) No treatment (n=3826)
Number (%) Odds ratio (95% CI)* Number (%) Odds ratio (95% CI)*
Age group (years)
15 to <20 698 (17·9%) 2318 (59·6%) 1 (ref) 873 (22·4%) 1 (ref)
20 to <25 329 (12·6%) 1555 (59·5%) 1·41 (1·22–1·63) 728 (27·9%) 1·81 (1·53–2·14)
25 to <30 464 (18·5%) 1474 (58·7%) 0·94 (0·82–1·08) 571 (22·8%) 1·02 (0·86–1·20)
30 to <35 589 (26·3%) 1276 (56·9%) 0·65 (0·57–0·74) 378 (16·8%) 0·53 (0·45–0·62)
35 to <45 1088 (32·0%) 1853 (54·5%) 0·51 (0·46–0·57) 457 (13·4%) 0·35 (0·30–0·40)
45 to <55 830 (35·6%) 1185 (50·9%) 0·43 (0·38–0·49) 314 (13·5%) 0·31 (0·27–0·37)
55 to <65 628 (37·3%) 802 (47·7%) 0·39 (0·34–0·45) 252 (15·0%) 0·34 (0·28–0·40)
≥65 469 (32·8%) 707 (49·5%) 0·46 (0·39–0·53) 253 (17·7%) 0·46 (0·38–0·55)
Sex
Male 2554 (27·3%) 5026 (53·7%) 1 (ref) 1784 (19·0%) 1 (ref)
Female 2541 (23·7%) 6144 (57·3%) 1·18 (1·11–1·25) 2042 (19·0%) 1·09 (1·01–1·18)
Household
Socioeconomic status
Poorest 1321 (25·3%) 2976 (56·9%) ·· 929 (17·8%) ··
Poor 2637 (25·2%) 5828 (55·8%) ·· 1986 (19·0%) ··
Least poor 1137 (25·8%) 2366 (53·6%) ·· 911 (20·6%) ··
Large size
No 3202 (26·5%) 6749 (55·9%) 1 (ref) 2129 (17·6%) 1 (ref)
Yes 1893 (23·6%) 4421 (55·2%) 1·03 (0·94–1·12) 1697 (21·2%) 1·24 (1·10–1·39)
Remote 
No 4206 (25·4%) 9167 (55·3%) ·· 3207 (19·3%) ··
Yes 889 (25·3%) 2003 (57·0%) ·· 619 (17·6%) ··
Urban or periurban location
No 3678 (25·9%) 7802 (55·0%) ·· 2694 (19·0%) ··
Yes 1417 (23·9%) 3368 (56·9%) ·· 1132 (19·1%) ··
*Multivariable logistic regression with robust SEs was done to account for household clustering. Odds ratios and 95% CIs are provided for the variables with the lowest 
Bayesian Information Criterion when all possible subsets of candidate predictors were modelled.
Table 4: Association between baseline individual and household characteristics and part or no treatment in adults
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treatments received by individuals across four rounds of 
MDA over 2 years, in which drugs were delivered door-
to-door by community health volunteers and in schools. 
Individuals not treated in a given round were more likely 
to miss treatment in later rounds, irrespective of the 
sociodemographic factors that affect reach and uptake 
overall. We found the greatest odds of non-treatment in 
those aged 15–30 years. This age group has previously 
been shown to harbour the highest rate of hookworm 
infections in Kwale county.13 The substantial degree of 
non-treatment in this group could have important 
implications for the feasibility of achieving sustained 
morbidity or transmission control.
In children, the factor most strongly associated with 
receipt of treatment in the first MDA round was the 
treatment status of the household head, and this factor 
was predictive independent of school attendance and 
household socioeconomic status and location. Receipt of 
treatment during MDA for trachoma, soil-transmitted 
helminths, schistosomiasis, and onchocerciasis has 
similarly been associated with treatment of the household 
head and is found to cluster within households.18,21–23 
Household clustering highlights the importance of 
adequate community engagement and sensitisation. As 
previously shown in the TUMIKIA trial and other studies, 
community engagement during MDA programmes can 
address perceptions about safety, effectiveness, and need 
for repeated treatment, and build trust and the demand 
for treatment.6–8,15,24
We found that women were more likely than men to 
receive part or no treatment with adjustment for age and 
household size. However, this pattern was reversed when 
women ineligible for treatment due to pregnancy or birth 
within the previous 2 weeks were excluded. Previous 
studies have noted lower treatment rates among women 
during MDA for lymphatic filariasis and onchocerciasis, 
which were attributed to ineligibility due to pregnancy 
and related safety concerns.7,20 WHO conditionally recom-
mends that women of reproductive age and pregnant 
women in the second or third trimester be included in 
deworming pro grammes.10 Our results sug gest that 
community-wide MDA can be an effective platform to 
reach this group, but in practice, additional strategies 
may be needed to ensure high coverage.25
Improved data collection and management solutions to 
identify, locate, and treat individuals within and across 
MDA rounds will be needed to reduce systematic non-
treatment. Prepopulating paper registers with individual 
information can facilitate targeting of individuals 
who were absent from the household during MDA, 
although this approach requires considerable logistical 
input. Additionally, it would still not ensure treatment of 
temporarily absent individuals, which was the most 
common recorded reason for non-treatment among 
adults in this analysis (appendix p 2). The use of mobile 
health approaches, such as SMS monitoring,26 District 
Health Information Software 227 and similar national 
systems,28 or smartphone-based electronic treatment 
registers29 to support data collection and decision making 
has been included in WHO guidelines.30 Although such 
interventions need to be further assessed,31 digital tracking 
approaches could improve targeting and treatment of 
urban and migrant populations, reduce costs, and increase 
coverage through real-time monitoring, and would in turn 
reduce systematic non-treatment.
Our analysis is subject to several limitations. The 
deworming activities were done by the Kwale county 
government, but financial, human, and in-kind resources 
were provided by the trial infrastructure. Whether 
similarly high coverage could be achieved during normal 
programmatic activities is unclear and might limit the 
generalisability of our results. Although our use of 
treatment register data eliminated recall bias and was 
representative of programmatic conditions, the lack of 
an individual census is an important limitation. We 
employed data officers for data abstraction and record 
linkage who were familiar with local languages and 
naming conventions, but errors might still have occurred 
when linking individual data longitudinally. Similarly, 
absence of data for an individual in a round might be due 
to incomplete data, absence during treatment, or 
permanent migration away from the study area. Towards 
addressing these limitations, alongside the main analysis 
that assumed a fixed cohort, we presented results of two 
approaches for censoring individuals without a treatment 
record during a specific and subsequent rounds.
In conclusion, we identified demographic subgroups in 
which the likelihood of not having any treatment recorded 
during multiple MDA rounds was increased, and found 
that non-treatment was associated across rounds. 
Modelling studies have suggested that soil-transmitted 
helminth infections in endemic communities become 
increasingly clustered as disease prevalence drops, 
determined in part by patterns of individual participation 
during MDA, with important consequences for the 
probability of achieving transmission interruption.32,33 
Developing a stronger empirical understanding of the 
effects of systematic non-treatment on transmission of 
soil-transmitted helminths and other neglected tropical 
diseases, and the identifi cation of new approaches to 
ensure treatment of identified subgroups, remain urgent 
priorities.
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